# *p53* Abnormalities in B-Cell Prolymphocytic Leukemia

By Daniela Lens, Pierre J.J.C. De Schouwer, Rifat A. Hamoudi, Munah Abdul-Rauf, Nahla Farahat, Estella Matutes, Tim Crook, Martin J.S. Dyer, and Daniel Catovsky

B-cell prolymphocytic leukemia (B-PLL) is an aggressive disorder of mature B cells with distinct clinical and pathologic features. To determine the incidence of abnormalities of *p53*, we analyzed 19 cases of B-PLL by DNA blot to assess loss of heterozygosity (LOH) at 17p13.3, by immunocytochemistry to assess *p53* expression, and by direct DNA sequencing of polymerase chain reaction-amplified exons 5 to 9 of the *p53* gene. LOH was detected in 10 of 19 (53%) cases, *p53* expression was detected in 8 of 17 (47%), and *p53* mutations were detected in 10 of 19 (53%) cases. The pattern of mutations was distinct from that observed in other B-cell malignancies. Six cases exhibited missense mutations; 4 were transversions and 2 were transitions. The G:C → A:T transition at cathepsin G dinucleotides commonly reported in *p53* mutations in chronic lymphocytic leukemia (CLL) and other hematologic malignancies was observed in only 1 case of B-PLL. Three cases exhibited deletions (ranging from 3 to 35 bp in length) and one case exhibited a 2-bp insertion. In 1 case, a 27-bp deletion resulted in the expression of a *p53* protein lacking 9 amino acids from the DNA binding region. All samples with *p53* mutation showed loss of germline *p53* sequences. However, 3 of 10 showed no LOH by Southern blot, indicating a localized deletion around the *p53* locus at 17p13.1. Five of the 10 cases with *p53* mutation exhibited detectable *p53* expression, including 4 cases with *p53* missense mutation and 1 case with deletion. Two of 7 cases with no detectable mutation of *p53* nevertheless overexpressed *p53*. Therefore, there was no correlation between protein expression and *p53* mutation in B-PLL. Our data indicate that the overall abnormalities of *p53* occurred in 14 of 19 (75%) cases of B-PLL. The frequency of *p53* mutation (53%) in B-PLL is the highest reported in B-cell malignancies and may be responsible for the frequent resistance to therapy of this disease. In addition, the pattern of *p53* mutation was different from that observed in CLL and other hematologic malignancies and may indicate that a distinct pathogenic mechanism operates in B-PLL.

© *1997 by The American Society of Hematology.*

**B**-CELL PROLYMPHOCYTIC leukemia (B-PLL) is a distinct leukemia of mature B cells[1,2] characterized by a high white blood cell count and splenomegaly without significant lymphadenopathy. The diagnosis is made by examination of peripheral blood film in which the predominant cells are prolymphocytes; a minimum of 55% of these cells must be found at presentation of the disease for this diagnosis to be established.[3]

The membrane phenotype of the prolymphocyte is quite distinct from that of chronic lymphocytic leukemia (CLL) but has similarities to that of other B-cell leukemias. They express strong SmIg that is IgM or IgM/IgD, pan-B−cell antigens, FMC7, and CD22 and they are usually negative for CD23. Several chromosome abnormalities have been described, including the t(11;14) (q13;q32), although these are not consistent. Additional abnormalities include trisomy of chromosome 12 and deletions of chromosomes 1, 3, and 6q.[4] However, little is known about the underlying molecular mechanisms of this rare disease that is frequently associated with resistance to therapy.[5]

The *p53* gene, which is located on chromosome 17p13.1, functions as a specific transcriptional activator[6] of genes controlling the G1 checkpoint of the cell cycle, ie, *mdm2*,[7] *p21* (*waf-1*),[8] and also appears to control the expression of certain genes involved in the control of programmed cell death or apoptosis, such as *Bax* and *bcl-2*.[9,10]

Mutations of the *p53* gene are the most common genetic alteration in human cancer[11,12] yet described. Most are missense mutations that change the amino acid composition of the protein. Such alterations can modify the conformation and stability of the *p53* protein and may result in the alteration of *p53*'s transcriptional activity as well as in an increase of the half life of the protein, allowing its detection by immunocytochemistry. In many cases, mutation of one allele is associated with deletion of the other allele, leading to inactivation of both normal *p53* alleles. Most *p53* mutations are clustered in four regions of the protein (residues 117-142, 171-181, 234-258, and 270-286) that are highly conserved among several different species.[12]

Mutations of the *p53* gene have been documented in a wide variety of hematologic malignancies, including Burkitt's lymphomas (41%), adult T-cell leukemia (24%), chronic myeloid leukemia in blast crisis (20% to 30%), chronic lymphocytic leukemia (12%), multiple myeloma (10%), and high-grade non-Hodgkin's lymphomas (NHL; 30%), whereas low-grade NHL rarely have alterations of *p53* unless they are transformed (reviewed in Imamura et al[13] and Newcomb[14]).

We present here an analysis of 17p allele loss, *p53* mutation, and *p53* protein expression in 19 cases of B-PLL. Molecular analysis showed a high incidence of *p53* mutations, loss of heterozygosity (LOH) at 17p, and *p53* expression. Moreover, the pattern of *p53* mutations was different from those reported in other lymphoid leukemias and may indicate a distinct pathogenic mechanism in this disease.

## MATERIALS AND METHODS

### *Patients*

Nineteen cases of B-PLL referred to our institution from 1990 to 1995 for diagnosis were selected for this study. Peripheral blood films for morphology analysis and immunologic markers were avail-

**Table 1. Main Clinical and Laboratory Data in 19 Cases of B-PLL**

| | |
|---|---|
| Age in years (mean ± SD) | 67 ± 12 |
| M/F ratio | 9/10 |
| Stage*† | |
| A | 1 |
| B | 6 |
| C | 7 |
| WBC × 10⁹ (mean ± SD) | 243 ± 163 |
| Splenomegaly† | 14/14 |
| Immunologic markers‡ | |
| CD19⁺ | 100% |
| Strong SmIgs | 100% |
| FMC7⁺ | 65% |
| CD5⁺ | 50% |

Abbreviation: WBC, white blood cells.
* Using Binet's staging for CLL.[42]
† Data available in 14 of 19 patients.
‡ Data were available in all of the patients studied.

able in all of the cases studied. Diagnosis was made on the basis of morphologic appearances and detailed immunophenotypic analysis by flow cytometry using the criteria established by the French-American-British group.[15] The main clinical and laboratory data are shown in Table 1.

### Immunocytochemistry

Immunocytochemistry was performed on cytospin preparations of peripheral blood or spleen mononuclear cell suspensions using the monoclonal antibodies (MoAbs) PAb1801 (Oncogene Science Inc, Cambridge, MA) and DO-1 (Santa Cruz Biotechnology Inc, Santa Cruz, CA) that recognize the amino acids 1-45 and 37-72, respectively, at the N-terminal epitope of mutant and wild-type *p53* protein; an indirect immunoperoxidase sandwich technique was also used.[16] Briefly, after fixation for 10 minutes in acetone, cytospins were incubated for 30 minutes with PAb1801 or DO-1 in phosphate-buffered saline (PBS), followed by a peroxidase-conjugated goat antimouse antibody for 30 minutes. Peroxidase antiperoxidase complexes were added to increase the staining intensity. The peroxidase reaction was performed by incubating for 10 minutes in a developing solution containing diaminobenzidine tetrahydrochloride 0.6 mg/mL (Dako, Glostrup, Denmark) in PBS with 0.1% of hydrogen peroxide. Cells were counterstained with Haematoxylin Gill (H.D. Supplies, Ayelsbury, Bucks, UK). The proportion of cells positively immunostained was evaluated by light microscopy under high power (magnification × 1,000) and at least 500 cells were scored from each sample. Positive control for *p53* expression was the CEM T-cell line, which carries a *p53* mutation and expresses abundant *p53*. Peripheral blood from a healthy donor was used as a negative control.

### Western Blot Analysis

Cells were lysed in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer (Sigma, St Louis, MO) and heated at 95°C for 5 minutes. Proteins were resolved on a SDS-polyacrylamide (13%) gel and transferred to nitrocellulose using a Transphor apparatus (Hoefer Pharmacia Biotech, San Francisco, CA) according to the instructions of the manufacturer. Filters were incubated in blotting solution (PBS, 0.05% Tween 20, 3% bovine serum albumin fraction V) for at least 1 hour at room temperature and then incubated with primary antibodies PAb1801, DO-1, or the antibody PAb 421 (Santa Cruz Biotechnology Inc) that recognize a C-terminal epitope of human *p53* protein[17] for 1 hour at room temperature. Filters were washed three times in PBS, 0.05% Tween 20 and incubated with antimouse horseradish peroxidase conjugate for 1 hour

at room temperature. Bound antibody was detected using the ECL Western blotting system (Amersham, Amersham, Bucks, UK) as described by the manufacturer.

### LOH Analysis

Conventional DNA blotting was performed as described.[18] Briefly, high molecular weight DNA was extracted from cryopreserved mononuclear fraction of peripheral blood by routine methods. Ten micrograms of DNA was digested to completion with *Pst* I restriction enzyme (Promega, Madison, WI). DNA fragments were electrophoresed in 0.7% agarose and transferred to positively charge nylon membranes (Hybond-N+; Amersham) by overnight capillary transfer in alkali. Filters were probed sequentially with p144-D6[19] (a D17S34 probe released as a 5.1-kb *Eco*RI insert) and pYNZ22[20] (a D17S30 probe released as a 1.7-kb *Bam*HI insert). Both probes were obtained from the American Tissue Collection Culture (Rockville, MD) and were labeled with $\alpha$-[32]P dCTP by the method of oligolabeling to a specific activity of greater than $3 \times 10^9$ dpm/$\mu$g DNA.

### Single-Strand Conformational Polymorphism (SSCP) Analysis of Exons 2-4 and 10-11

To screen for *p53* mutations outside the highly conserved region of *p53*, SSCP was used to analyze exons 2, 3, 4, 10, and 11. Primers for SSCP were obtained from Clontech (Human Amplimer Panel; Clontech, Palo Alto, CA). SSCP reactions were performed in a volume of 10 $\mu$L and contained 10 mmol/L Tris-HCl, pH 8.3, 50 mmol/L KCl, 1.5 mmol/L MgCl$_2$, 0.01% gelatine, 200 ng of genomic DNA, 200 $\mu$mol/L of each deoxyribonucleoside triphosphate (dNTP), 2.5 pmol each primer, 0.1 $\mu$L of 10 $\mu$Ci/$\mu$L [$\alpha$-^{32}P] dCTP, and 0.2 U of *Taq* DNA polymerase. Thirty-five cycles of amplification were performed of 95°C for 30 seconds, 66°C for 45 seconds, and 72°C for 90 seconds. Samples were diluted twofold in formamide dye loading buffer, heated to 95°C for 5 minutes, chilled on ice, and then resolved in 1× TBE on nondenaturing 6% polyacrylamide gels with or without 10% glycerol. Dried gels were exposed to x-ray film for 2 to 24 hours. For each exon, control DNA containing a known missense mutation was included in the analysis.

### p53 Sequencing

Sequencing of exons 5 to 9 of *p53* was performed by polymerase chain reaction (PCR) amplification followed by direct automated sequencing of double-stranded DNA using termination nucleotides tagged with fluorescent dyes.

*PCR amplification.* PCR was performed using 200 ng of DNA, 1.5 mg MgCl$_2$, 200 $\mu$mol/L of each dNTPs, 1 $\mu$mol/L of each primer, 0.4 $\mu$L of *Taq* polymerase enzyme (Promega), and 5 $\mu$L of 10× Taq buffer (Promega) in a final volume of 50 $\mu$L. The cycling profile comprised 30 cycles of denaturation (92°C for 45 seconds), annealing (61°C for exons 5, 8, and 9 and 62°C for exons 6 and 7 for 45 seconds), and extension (72°C for 45 seconds). PCR amplification was performed in a Biometra (Goettingen, Germany) thermal cycler.

*DNA nucleotide primers.* The primers were obtained from Oswell (University of Edinburgh, Edinburgh, UK) and used for PCR and DNA sequencing. These primers were designed using the OLIGO 4.1 program to anneal to intronic sequences immediately flanking the respective exons. Their sequences were as follows: exon 5 sense strand, 5′ ACTTGTGCCCTGACTTTCAACT 3′; exon 5 antisense strand, 5′ CAATCAGTGAGGAATCAGAGGC 3′; exon 6 sense strand, 5′ TCAGATAGCGATGGTGAGCAG 3′; exon 6 antisense strand, 5′ GCCACTGACAACCACCCTTA 3′; exon 7 sense strand, 5′ GCGACAGAGCGAGATTCCA 3′; exon 7 antisense strand, 5′ GAAATCGGTAAGAGGTGGGC 3′; exon 8 sense strand, 5′ GGAGTAGATGGAGCCTGGTTT 3′; exon 8 antisense strand, 5′ GGTGATGAAAAGTGAATCTGAGGC 3′; exon 9 sense

Table 2. Summary of *p53* Abnormalities in 19 Cases of B-PLL

| Patient No. | 17p13 LOH | p53 Protein* (%) | p53 Mutation† | | | |
|---|---|---|---|---|---|---|
| | | | Codon | Nucleotide Substitutions | Amino Acid Substitution | Type of Mutation |
| 1 | Yes | + (48%) | 205 | TAT→TGT | Tyr→Cys | Ts |
| 2 | Yes | ++ (51%) | 248 | CGG→CAG | Arg→Gln | Ts CpG |
| 3 | Yes | ++ (81%) | 176 | TGC→AGC | Cys→Ser | Tv |
| 4 | Yes | ++ (90%) | 275 | 27-bp DEL | In frame | |
| 5 | Yes | — | 237 | 5-bp DEL | Frameshift | |
| 6 | Yes | — | 284 | 2-bp INS | Frameshift | |
| 7 | Yes | — | 266 | GGA→GTA | Gly→Val | Tv |
| 8 | No | — | 161 | GCC→CCC | Ala→Pro | Tv |
| 9 | No | ++ (59%) | 194 | CTT→CAT | Leu→His | Tv |
| 10 | No | ++ (47%) | 293 | 35-bp DEL | Frameshift | |
| 11 | Yes | ++ (87%) | | | | |
| 12 | Yes | — | | | | |
| 13 | Yes | ND | | | | |
| 14 | No | + (78%) | | | | |
| 15 | No | — | | | | |
| 16 | No | — | | | | |
| 17 | No | — | | | | |
| 18 | No | — | | | | |
| 19 | No | ND | | | | |

\* Intensity of immunocytochemical staining; +, moderate; ++, strong; ND, not determined.

† Not found in cases no. 11 through 19.

strand, 5′ GGAGACCAAGGGTGCAGTTAT 3′; exon 9 antisense strand, 5′ GTTAGTTAGCTACAACCAGGAGCC 3′.

*Direct DNA sequencing of PCR products.* PCR products were first purified using phenol/chloroform (1:1) extraction and precipitation with isopropanol (100%) and 7.5 mol/L ammonium acetate. The same primers used for generating the PCR products were also used for the sequencing reactions. Other reagents were supplied in the ReadyReaction Taq DyeDeoxy termination sequencing kit (Applied Biosystems [ABI], Foster City, CA). Both strands were sequenced for each exon. The ABI protocol was followed for the cycle sequencing of PCR products with slight modifications. One microliter of the purified PCR product (approximately 40 ng) was used and the primer concentration was 10 pmol/$\mu$L. Unincorporated nucleotides were removed from the extended products using two phenol/chloroform steps followed by an ethanol precipitation step. Samples were loaded on a 7% denaturing polyacrylamide gel, and the electrophoresis was performed on a Model 373A DNA Sequencer (ABI). All PCR products were sequenced in both orientations. Because of the possibility of *Taq* polymerase DNA incorporation errors, PCR products of the mutated cases were sequenced from two separate PCR reactions. Identical results were obtained in all cases.

## RESULTS

To determine the frequency and the nature of the abnormalities of *p53* in B-PLL, we undertoook DNA blotting to assess LOH, direct DNA sequencing of *p53* exons 5 through 9, and immunocytochemistry. The results have been summarized in Table 2.

### LOH Analysis

We tested allelic deletion at 17p13 using p144-D6 and pYNZ22, two highly informative polymorphic probes mapping near to *p53* locus. Using both probes, a constitutive loss can be assessed within 95% confidence limits when both probes show a loss of one 17p allele, even when corresponding normal tissue is not available for comparison.[11] Results

are shown in Fig 1. In 10 of 19 (53%) cases, only one band was detected with both probes (Table 2).

### Sequencing Analysis of p53 Gene

Nineteen cases of B-PLL were analyzed for the presence of mutations in the highly conserved region of *p53* (exons 5 through 9) by automated cycle sequencing of PCR products. Given the relatively high rate of base misincorporation associated with PCR,[11] all mutations found were confirmed by performing a second PCR reaction and resequencing.

Mutations were detected in 10 cases (Table 2); 4 were localized in exon 8 and 2 in each of exons 5, 6, and 7, respectively. Examples of *p53* mutations are shown in Fig 2. The following types of mutations were found: 6 cases of missense mutations, 3 cases of deletions (1 with a 5-bp deletion, 1 with a 27-bp deletion, and 1 with a 35-bp deletion) and 1 case with 2-bp insertion. Among the base substitution mutations, 4 were transversions (change of a pyrimidine to another pyrimidine or a purine to another purine) and 2 were transitions (change of a pyrimidine to a purine or vice versa). As shown in Table 2, the mutations in the cases with *p53* deletions or insertions were localized in the central part of the molecule (3 in exon 8 and 1 in exon 7), whereas the cases with missense mutation were scattered in exons 5 through 8. Only in 1 case did the mutation fall in a hot spot nucleotide (Arg248). Analysis of the chromatograms at the site of the mutation showed that, in all samples with altered sequences, there was no additional signal corresponding to the normal sequence, indicating that, in B-PLL, all *p53* mutations were accompanied by the loss of the other allele.

### SSCP Analysis

SSCP analysis was performed to screen for mutations in exons 2, 3, 4, 10, and 11 in those cases in which direct DNA

**Fig 1. LOH analysis at 17p13.3 in B-PLL cases.** Genomic DNA from the samples studied were digested with *Pst* I, subjected to Southern blot, and probed with the clone p144-D6. Cases were scored positive for LOH when displaying only one allelic band with both probes. Nine of the B-PLL cases show only one band with p144-D6. However, in case no. 8, two bands were observed with pYNZ22 probe. Lane 0, control DNA from a normal sample.

sequencing in the highly conserved region of *p53* gene did not show any mutations. No altered migration was observed in any of these cases (Fig 3).

*Expression of* p53 *Protein*

Immunostaining using PAb1801 MoAb directed against the N-terminal residues 1-45 was performed in 17 cases of B-PLL in which sufficient suitable material was available as well as in the control positive CEM cell line.[21] The CEM cell line showed a strong nuclear immunostaining in 90% of cells and 8 B-PLL cases were stained positive for *p53*. The percentage of positive cells varied from 45% to 90% (Table 2). Representative examples of immunocytochemistry are shown in Fig 4. In 6 of 8 positive cases, we repeated the



**Fig 2. Analysis of a *p53* mutation by PCR direct sequencing using fluorescent termination nucleotides.** A chromatogram of control DNA is shown in (A). (B) and (C) correspond to chromatograms of the PCR product of exon 8 of *p53* from a mutated case sequenced from both ends. A single base pair substitution (G → T) was detected in this case. Arrows point to the site of mutation. Note that the signal corresponding to the germline nuleotide could not be detected.

Fig 3.  Representative SSCP analysis of genomic DNA from B-PLL showing absence of mutations in exons 4 and 10 of *p53*. SSCP was performed as described in the Materials and Methods. Abnormally migrating conformers in control DNAs are indicated with arrows. (A) SSCP of exon 4. Lane C, control DNA with known missense mutation at codon 102 of *p53*. Lanes 1 through 5, DNA from individual B-PLL cases. (B) SSCP of exon 10. Lane C, control DNA with a known missense mutation at codon 336 of *p53*. Lanes 1 through 7, DNA from individual B-PLL cases.

immunocytochemistry with another anti-*p53* antibody (DO-1) and the same results were obtained (data not shown).

*Relationship Between LOH,* p53 *Mutation, and Protein Expression*

Among the 10 B-PLL cases with apparent LOH on 17p, 7 cases showed mutation in the residual allele. In the other 3 cases, no structural alteration of *p53* gene was found. On the other hand, 3 cases with *p53* mutation showed two bands on Southern blot (Table 2). However, sequencing analysis did not show residual wild-type signal. These data suggest the presence of a more localized deletion adjacent to the *p53* gene in these 3 cases.

The 8 cases of B-PLL with positive immunostaining comprised 4 cases with missense mutation, 2 cases with short deletions, and 2 cases with normal *p53* sequence. The 2 cases carrying deletions (cases no. 4 and 10) and 1 of the cases without mutation (case no. 11) were further assessed by Western blot using PAb 1801 and DO-1 antibodies as a probe. A band of 53 kD that comigrated with the *p53* band in the CEM cell line control was recognized by the antibody in samples from cases nos. 4 and 11 but not in samples from case no. 10 (Fig 5A) The same results were observed in cases no. 4 and 10 when using an MoAb directed to the C-terminus of *p53* (Pab421; Fig 5B). Figure 5C showed the predicted amino acid sequence of the mutated protein of case no. 4 compared with the wild-type *p53* protein sequence.

## DISCUSSION

Mutations of *p53* are the most common genetic abnormality in cancer.[12,22] They have been extensively studied in various malignancies of mature B cells, including NHL,[23-26] CLL,[27-30] and myeloma.[31] In NHL and CLL, it is clear that *p53* mutation is a secondary event often associated with progression or transformation.[26,27,32,33] In this study, we report the frequency and nature of *p53* abnormalities in B-PLL, a rare and aggressive form of leukemia.

First, allelic loss at 17p (eg, LOH) was studied by Southern blot using two highly polymorphic probes that detect minisatellite sequences at 17p13.3. Fifty-three percent of B-PLL cases showed only one band. Because there is a great chance (95%) of detecting a difference between the restriction fragment lengths with these probes if two alleles are present, it is likely that cases with a single band have one allele of chromosome 17p13.3 deleted.[11,23]

Mutations of *p53* gene were studied using direct sequencing of PCR products. We limited our analysis to the highly conserved region between exons 5 and 9 that prior studies[14,34,35] showed to contain 80% to 95% of all *p53* mutations in a variety of human cancers, including hematologic malignancies.

The overall frequency of *p53* mutation in B-PLL was 53%, the highest incidence of *p53* mutation reported within lymphoid neoplasias, reaching figures found in solid tumors. Concerning the mutational spectrum of *p53*, we found that, unlike other B-cell malignancies in which substitution accounted for 90% of *p53* mutations (data obtained from the *p53* mutational database[36]), 40% of the mutations detected in B-PLL were either deletions or insertions. Three cases exhibited deletions of 5, 27, and 35 bp and 1 case exhibited a 2-bp insertion. These mutations were localized in the central part of the molecule (exons 7 and 8). Among the missense mutations, 4 cases were transversions and 2 cases were transitions. This pattern is different from that found by us in CLL (data not shown) and reported in other lymphoid malignancies that consist primarily of G → A transitions at cathespin G (CpG) dinucleotides.[14,34,35,37] In addition, according to the *p53* mutational database,[36] 8 of the 10 changes observed in the *p53* gene in B-PLL had not been previously reported in hematologic malignancies. This difference in the spectrum of *p53* mutations may reflect the etiologic contribution of distinct exogenous or endogenous factors to B-PLL pathogenesis.

Deletions/insertions are a type of mutations that were pre-

Fig 4.   Immunocytochemistry of *p53* protein using PAb1801 antibody. (A) Control positive CEM T-cell line showing most of the cells to be positive. (B) Case with a *p53* mutation and with 80% of cells positive. (C) Case which is negative for *p53* protein despite exhibiting a *p53* mutation.

A

1   2   3   4   5

p53

B

1   2   3        4   5   6

p53                              p53

C

```
wt p53    1  MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDI  50
             |||||||||||||||||||||||||||||||||||||||||||||||||
case# 4   1  MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDI  50

wt p53   51  EQWFTEDPGPDEAPRMPEAAPRVAPAPAAPTPAAPAPAPSWPLSSSVPSQ 100
             |||||||||||||||||||||||||||||||||||||||||||||||||
case# 4  51  EQWFTEDPGPDEAPRMPEAAPRVAPAPAAPTPAAPAPAPSWPLSSSVPSQ 100

wt p53  101  KTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDST 150
             |||||||||||||||||||||||||||||||||||||||||||||||||
case# 4 101  KTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDST 150

wt p53  151  PPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGN 200
             |||||||||||||||||||||||||||||||||||||||||||||||||
case# 4 151  PPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGN 200

wt p53  201  LRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRP 250
             |||||||||||||||||||||||||||||||||||||||||||||||||
case# 4 201  LRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRP 250

wt p53  251  ILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEEENLRKKGEPHHELP 300
             |||||||||||||||||||||||||||:         ||||||||||||||
case# 4 251  ILTIITLEDSSGNLLGRNSFEVRVS.........EEENLRKKGEPHHELP 291

wt p53  301  PGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALEL 350
             |||||||||||||||||||||||||||||||||||||||||||||||||
case# 4 292  PGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALEL 341

wt p53  351  KDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD 393
             |||||||||||||||||||||||||||||||||||||||||||
case# 4 342  KDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD 384
```

Fig 5. (A) Immunoblotting with DO-1 antibody. Lane 1, CEM positive control; lane 2, case no. 11 with no *p53* mutation; lane 3, case no. 4 with a 27-bp intragenic deletion; lane 4, case no. 10 with a 35-bp deletion; lane 5, case no. 5 with a 5-bp deletion at exon 7 and *p53* protein negative by immunocytochemistry. (B) Immunoblotting of whole cell lysates from cases no. 4 (lanes 1 and 5) and case no. 10 (lanes 2 and 4) with PAb 1801 and PAb 421 antibodies. Case no. 4 (lanes 1 and 5) showed a 53-kD band with both antibodies and no band is observed with any of the antibodies in case no. 10 (lanes 2 and 4). Lane 3 and 6 correspond to CEM-positive control. (C) Comparison of the predicted amino acid sequence of case no. 4 with the wild-type *p53* protein sequence.

viously reported to be scattered along the *p53* gene and not only confined to exons 5 through 9. Thus, we performed SSCP analysis in cases in which mutations were not found in exons 5 through 9 to screen for mutations in the rest of the *p53* coding region. No altered migration was observed in any of these cases, suggesting that *p53* mutations in B-PLL may be preferentially localized in the highly conserved DNA-binding region.

Several observations support the concept that *p53* mutation is accompanied by loss of the remaining allele.[11,38] In this series, no additional signal corresponding to the normal *p53* sequence was detected in any of the mutated cases, implying deletion of the nonmutated allele. These events may occur simultaneously or one may precede the other

during the disease progression. When *p53* mutation and LOH results were compared, 3 cases with LOH without mutation in the coding region of *p53* gene were detected, which may suggest that in B-PLL deletion preceded mutation. In contrast, 3 cases with mutation and no remaining signal of wild-type sequence showed two bands by Southern blot with p144-D6 or pYNZ22 probes. This finding would imply that the break of the deletion in these cases was between the *p53* locus at 17p13.1 and 17p13.3 where pYNZ22 and p144-D6 map. Interstitial deletions involving *p53* but not the distal part of 17p have been previously reported in Burkitt's lymphomas and in breast cancer.[23,39]

Positive immunostaining is generally thought to reflect the presence of *p53* mutations, because mutation usually results

in protein stabilization and an increase in its half life. Eight of 17 B-PLL cases studied were positive for *p53* expression by immunocytochemistry. However, in this series, there was not a strict correlation between mutation and detectable *p53* expression. Thus, in 2 cases with positive immunostaining, we were unable to detect *p53* mutations either by direct sequencing of exons 5 through 9 or by SSCP of exons 2, 3, 4, 10, and 11. In 1 of these cases (no. 11), the immunocytochemistry was confirmed by Western blotting, which showed the presence of apparently wild-type protein. In these cases, mechanisms other than mutation of the protein coding sequences may result in overexpression and/or stabilization of *p53* protein. Similarly, 2 cases with missense mutation were unexpectedly negative for *p53* protein. One possible explanation for this is a false-negative immunocytochemical result due to poor preservation of the antigen. Another possibility is that these particular point mutations may result in loss of *p53* function without protein stabilization.

It has also been suggested from previous studies that nonsense or frameshift mutations may result in negative immunostaining.[37,40] In this series, in 2 cases, 1 with a deletion of 5 bp and another with an insertion of 2 bp, this was indeed the case and no positively staining cells were observed. However, we unexpectedly found 2 cases (cases no. 4 and 10 with deletions of 27 and 35 bp, respectively) that both exhibited a high percentage of positively staining cells. To ensure that this result was not artifactual, the staining was repeated with different MoAbs that recognize a different epitope within the amino terminus of the *p53* protein and similar results were obtained. To corroborate these results, Western blotting with N- and C-terminal MoAbs was performed. In case no. 4, all MoAbs detected a 53-kD protein confirming the immunocytochemistry. Thus, in this case, it appears that the deletion of 27 bp from exon 8 resulted in the deletion of 9 amino acids from the DNA-binding region of *p53*, but yet also resulted in protein stabilization. In contrast, case no. 10 was negative by Western blotting using the same reagents. The reasons for this discrepancy are not clear but may reflect a false-positive immunocytochemical reaction, because this was performed on cryopreserved cytospin preparations that may not be optimal. However, overall, our results indicate that in B-PLL immunocytochemistry may not always correlate with *p53* mutation. Similar results have been reported by others in other lymphoid malignancies.[39,41,42]

In summary, our results indicate that the overall abnormalities of the *p53* gene occur in 75% of cases of B-PLL; this is the highest frequency of *p53* abnormalities reported in any hematologic malignancy. Therefore, disruption of the *p53* pathway is probably an important event in the pathogenesis of B-PLL. Moreover, both the pattern and the distribution of mutations were distinctive from those observed in other B-cell malignancies, implying the operation of distinct etiologic mechanisms. B-PLL is known for its aggressive clinical course and poor response to chemotherapy,[5] with a median survival of 3 years.[41] It is likely that the abnormalities of *p53* shown in this report may underline the resistance to treatment and aggressive course of this disease.

## ACKNOWLEDGMENT

## REFERENCES

1. Galton DAG, Goldman JM, Wiltshaw E, Catovsky D, Henry K, Goldenberg GJ: Prolymphocytic leukaemia. Br J Haematol 27:7, 1974

2. Catovsky D, Galetto J, Okos A, Galton DAG, Wiltshaw E, Stathopoulos G: Prolymphocytic leukemia of B and T cell type. Lancet 2:232, 1973

3. Melo JV, Wardle J, Chetty M, England J, Lewis SM, Galton DA, Catovsky D: The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. III. Evaluation of cell size by morphology and volume measurements. Br J Haematol 64:469, 1986

4. Brito-Babapulle V, Pittman S, Melo JV, Pomfret M, Catovsky D: Cytogenetic studies on prolymphocytic leukemia. I. B-cell prolymphocytic leukemia. Hematol Pathol 1:27, 1987

5. Kay NE, Suen R, Ranheim E, Peterson LC: Confirmation of Rb gene defects in B-CLL clones and evidence for variable predominance of the Rb defective cells within the CLL clone. Br J Haematol 84:257, 1993

6. Volgenstein B, Kinzler KW: *p53* function and dysfunction. Cell 70:523, 1992

7. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the *p53* protein and inhibits *p53*-mediated transactivation. Cell 69:1237, 1992

8. El-Deiry W, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Volgenstein B: Waf1, a potential mediator of *p53* tumor suppression. Cell 75:817, 1993

9. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC: Tumor suppressor *p53* is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799, 1994

10. Miyashita T, Reed JC: Tumor suppressor *p53* is a direct transcriptional activator of the human bax gene. Cell 80:293, 1995

11. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Volgenstein B: Mutations in the *p53* gene occur in diverse human tumour types. Nature 342:705, 1989

12. Levine AJ, Momand J, Finlay CA: The *p53* tumour suppressor gene. Nature 351:453, 1991

13. Imamura N, Kuramoto A, Ishihara H, Shimizu S: Detection of high-incidence of h-ras oncogene point mutations in acute myelogenous leukemia. Am J Hematol 211:151, 1993

14. Newcomb EW: *p53* gene-mutations in lymphoid diseases and their possible relevance to drug-resistance. Leuk Lymphoma 17:211, 1995

15. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C, French-American-British (FAB) Cooperative Group: Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J Clin Pathol 42:567, 1989

16. Mason D, Cordell J, Abdulaziz A, Naiem M, Bordenave G: Preparation of peroxidase anti-peroxidase (PAP) complexes for immunohistological labelling of monoclonal antibodies. J Histochem Cytochem 11:1114, 1982

17. Harlow E, Crawford LV, Pim DC, Williamson NM: Monoclonal antibodies specific for simian virus 40 tumour antigen. J Virol 39:861, 1981

18. Dyer MJS, Heward JM, Zani VJ, Buccheri V, Catovsky D: Unusual deletions within the immunoglobulin heavy-chain locus in acute leukemias. Blood 82:865, 1993

19. Kondoleon S, Vissing H, Luo XY, Magenis RE, Kellogg J, Litt M: A hypervariable RFLP on chromosome 17p13 is defined by an arbitrary single copy probe p144-D6 [HGM9 No. D17S34]. Nucleic Acids Res 15:10605, 1987

20. Nakamura Y, Ballard L, Leppert M, O'Connell PO, Lathrop GM, Lalouel J-M, White R: Isolation and mapping of a polymorphic DNA sequence (pYNZ22) on chromosome 17p [D17S30]. Nucleic Acids Res 16:5707, 1988

21. Cheng J, Haas M: Frequent mutations in the *p53* tumor suppressor gene in human leukemia T-cell lines. Mol Cel Biol 10:5502, 1990

22. Caron de Fromentel C, Soussi T: TP53 Tumor suppressor gene: A model for investigating human mutagenesis. Genes Chromosom Cancer 4:1, 1992

23. Farrell PJ, Gordon JA, Shanahan F, Vousden KH, Crook T: *p53* is frequently mutated in Burkitt's lymphoma cell lines. EMBO J 10:2879, 1991

24. Adamson DJA, Thompson WD, Dawson AA, Bennett B, Haites NE: *p53* mutation and expression in lymphoma. Br J Cancer 72:150, 1995

25. Baldini L, Fracchiolla NS, Cro LM, Trecca D, Romitti L, Polli E, Maiolo AT, Neri A: Frequent *p53* gene involvement in splenic-cell leukemia/lymphomas of possible marginal zone origin. Blood 84:270, 1994

26. Louie DC, Offit K, Jaslow R, Parsa NZ, Murty VVVS, Schluger A, Chaganti RSK: *p53* overexpression as a marker of poor prognosis in mantle cell lymphoma with t(11;14) (q13;q32). Blood 86:2892, 1995

27. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R: *p53* mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic-leukemia. Proc Natl Acad Sci USA 88:5413, 1991

28. Fenaux P, Preudhomme C, Lai JL, Quiquandon I, Jonveaux P, Vanrumbeke M, Sartiaux C, Morel P, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerckaert JP: Mutations of the *p53* gene in B-cell chronic lymphocytic leukemia: A report on 39 cases with cytogenetic analysis. Leukemia 6:246, 1992

29. El Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, Newcomb EW: *p53* gene mutation in B-cell chronic lymphocytic leukemia is associated with drug-resistance and is independent of mdr1/mdr3 gene expression. Blood 82:3452, 1993

30. Gaidano G, Newcomb EW, Gong JZ, Tassi V, Neri A, Cortelezzi A, Calori R, Baldini L, Dalla-Favera R: Analysis of alterations of oncogenes and tumor-suppressor genes in chronic lymphocytic-leukemia. Am J Pathol 144:1312, 1994

31. Corradini P, Inghirami G, Astolfi M, Ladetto M, Voena C, Ballerini P, Gu W, Nilsson K, Knowles DM, Boccadoro M, Pileri A, Dalla-Favera R: Inactivation of tumor suppressor genes, *p53* and rb1 in plasma cell dyscrasias. Leukemia 8:758, 1994

32. Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RSK, Dalla-Favera R: P53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82:2289, 1993

33. Aguilar-Santelises M, Magnusson KP, Wiman KG, Mellstedt H, Jondal M: Progressive B-cell chronic lymphocytic leukemia frequently exhibits aberrant *p53* expression. Int J Cancer 58:474, 1994

34. Hollstein M, Sidransky D, Vogelstein B, Harris CC: *p53* mutations in human cancers. Science 253:49, 1991

35. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the *p53* tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855, 1994

36. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R, Harris CC: Database of *p53* gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22:3551, 1994

37. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B: Multifactorial analysis of *p53* alteration in human cancer: A review. Int J Cancer 57:1, 1994

38. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Wilson JKV, Hamilton S, Vogelstein B: P53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50:7717, 1990

39. Thompson AM, Anderson TJ, Condie A, Prosser J, Chetty U, Carter DC, Evans HJ, Steel CM: *p53* allele losses, mutations and expression in breast cancer and their relationship to clinicopathological parameters. Int J Cancer 50:528, 1992

40. Harris CC, Hollstein M: Clinical implications of the *p53* tumor suppressor gene. N Engl J Med 329:1318, 1993

41. Melo JV, Catovsky D, Gregory WM, Galton DA: The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. IV. Analysis of survival and prognostic features. Br J Haematol 65:23, 1987

42. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198, 1981